In light of the potential that targeting GRPs have in improving glioblastoma therapy, various studies have sought to inhibit GRP78 using various agents and to examine their potential to be used in conjunction with current conventional therapies and in clinical settings. This evidence concerns the gene HSPA5 and glioblastoma.